STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on STAA. Canaccord Genuity Group upped their price objective on STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a research report on Tuesday, April 26th. Needham & Company LLC reiterated a "buy" rating and set a $87.00 target price on shares of STAAR Surgical in a research note on Tuesday, May 3rd. BTIG Research reiterated a "buy" rating and set a $98.00 target price on shares of STAAR Surgical in a research note on Saturday, April 23rd. Finally, Canaccord Genuity Group increased their price target on STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a research report on Tuesday, April 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $92.00.
STAAR Surgical Trading Down 1.2 %
NASDAQ:STAA opened at $84.51 on Monday. The stock has a market capitalization of $4.04 billion, a PE ratio of 145.71 and a beta of 1.09. The firm's 50 day moving average is $72.94 and its 200 day moving average is $69.89. STAAR Surgical has a 12 month low of $49.03 and a 12 month high of $163.08.
Insider Activity
In related news, CEO Caren L. Mason sold 35,000 shares of the company's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $57.49, for a total value of $2,012,150.00. Following the completion of the transaction, the chief executive officer now directly owns 83,645 shares in the company, valued at $4,808,751.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.60% of the company's stock.